Login to Your Account



Synosia Therapeutics Nabs Potential $725M Pact with UCB

By Nuala Moran


Wednesday, October 13, 2010
LONDON – Synosia Therapeutics sealed a $725 million pact on its two lead drugs for treating Parkinson's disease with UCB Pharma, and announced the closing of a third round funding of $30 million. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription